Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Travere Therapeutics arrives at its October 29 earnings date carrying a stock down 21% in one month and options positioning that has turned sharply more cautious than at any point in recent memory.
The starkest signal this week is in options. The put/call ratio jumped to 0.86 on Friday, well above its 20-day average of 0.56. The z-score of 3.52 puts that reading more than three and a half standard deviations above the norm, the most defensive tilt the options market has shown all year. That kind of demand for downside protection, arriving eleven days before the Q3 print, reflects genuine unease rather than routine hedging. The stock fell 6% on Friday alone and is now at $49.60, down roughly 20% from a month ago when analysts were still raising targets into the high $70s.
Short interest is elevated but not driving the story. Bears hold around 14.2% of the free float, a level that has been largely stable for the past month with only a modest 6% build over 30 days. The borrow market offers no additional squeeze pressure. Availability is extremely loose at more than 2,100% of short interest, meaning there are far more shares available to lend than are currently borrowed. Cost to borrow is around 0.49%, barely above the risk-free rate. With borrow this cheap and abundant, short positioning is a considered macro bet rather than a crowded trade near a squeeze threshold.
The Street remains broadly constructive, but the most recent target raises are now several weeks stale and the stock has fallen sharply below them. Guggenheim lifted its target to $89 in late September; HC Wainwright holds at $67; the consensus mean sits at $75. Every one of those targets is well above the current $49.60, implying roughly 50% return potential on the mean, though none of those calls have been refreshed since the October selloff. The bull case rests on Filspari's franchise durability: a USPTO notice of allowance could extend US coverage for FSGS methods into October 2037, and physician surveys suggest FSGS use could grow from roughly 15% to 30% of eligible patients within six months. The bear case is capital and regulatory risk. Accelerated approval pathways may still require additional data, and the company may need to tap markets to fund its pipeline, a concern that weighs harder when the stock is already under pressure. The PE multiple has compressed to around 10x trailing earnings, down from close to 14x a month ago, and price-to-book has dropped to 8.7x, a meaningful de-rating that suggests the market is reassigning risk rather than just marking down with peers.
It is worth noting that biotech peers had a rough week too, so some of TVTX's pain is sector-wide. SVRA fell nearly 10% on the week, PRAX dropped 7%, and RVMD lost more than 6%. TVTX's 5% weekly decline sits roughly in the middle of that peer group, suggesting the sector is under pressure broadly, though the options skew on TVTX is notably sharper than what that general selloff alone would typically produce.
On the alternative data side, Medicaid prescription volumes for Travere's drugs rose for a third consecutive quarter and were up 27% year-on-year in Q1 2026, the most recent period available from CMS data. That trajectory supports the commercial growth narrative the bulls are leaning on, though it covers a period that ended before the recent stock weakness began and is not a leading indicator of the coming print.
The insider register adds context without adding comfort. All recent trades by the CEO and CCO in September were executed under pre-arranged 10b5-1 plans, so the net outflow of roughly $58.6 million over 90 days reflects scheduled compensation liquidation rather than discretionary selling. There is no activist on the 13D register. Janus Henderson remains the largest holder at around 12% of shares, with BlackRock and FMR LLC also holding significant stakes, each adding modestly in recent filings.
What to watch next is straightforward: the October 29 earnings call will need to address both the Filspari revenue trajectory and any update on patent exclusivity for FSGS, given that the patent angle is the single most cited reason for the recent target upgrades. The earnings history here is asymmetric: the last comparable quarterly print in August produced a 14% one-day gain. The one before that fell 2%. With options pricing in the most defensive setup of the past year, the market is clearly positioned for the downside tail.
See the live data behind this article on ORTEX.
Open TVTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
